Who are LY2189265's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lixisenatide (AVE0010), Ozempic®, Benaglutide Injection, Exenatide twice daily (BID), Liraglutide injection, Semaglutide Pen Injector.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ly2189265.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

LY2189265 — Competitive Intelligence Brief

LY2189265 (LY2189265) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GLP-1 receptor agonist. Area: Diabetes.

phase 3 GLP-1 receptor agonist GLP-1R Diabetes Biologic Live · refreshed every 30 min

Target snapshot

LY2189265 (LY2189265) — Eli Lilly and Company. LY2189265 is a long-acting GLP-1 receptor agonist that mimics glucagon-like peptide-1 to improve blood glucose control by stimulating insulin secretion and reducing glucagon release.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
LY2189265 TARGET	LY2189265	Eli Lilly and Company	phase 3	GLP-1 receptor agonist	GLP-1R
Lixisenatide (AVE0010)	Lixisenatide (AVE0010)	Sanofi	marketed	GLP-1 receptor agonist	GLP-1R
Ozempic®	Ozempic®	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	marketed	GLP-1 receptor agonist	GLP-1R (glucagon-like peptide-1 receptor)
Benaglutide Injection	Benaglutide Injection	The Affiliated Hospital of Qingdao University	marketed	GLP-1 receptor agonist	GLP-1R
Exenatide twice daily (BID)	Exenatide twice daily (BID)	Eli Lilly and Company	marketed	GLP-1 receptor agonist	GLP-1R
Liraglutide injection	Liraglutide injection	Unidad de Cirugia Bariatrica Hospital Civil Dr. Juan I. Menchaca	marketed	GLP-1 receptor agonist	GLP-1R
Semaglutide Pen Injector	Semaglutide Pen Injector	University of Pennsylvania	marketed	GLP-1 receptor agonist	GLP-1R

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GLP-1 receptor agonist class)

Hanmi Pharmaceutical Company Limited · 30 drugs in this class
Eli Lilly and Company · 8 drugs in this class
Novo Nordisk A/S · 6 drugs in this class
GlaxoSmithKline · 6 drugs in this class
Sanofi · 4 drugs in this class
AstraZeneca · 4 drugs in this class
Daewoong Pharmaceutical Co. LTD. · 4 drugs in this class
Hangzhou Sciwind Biosciences Co., Ltd. · 3 drugs in this class
Jiangsu Hansoh Pharmaceutical Co., Ltd. · 2 drugs in this class
Huons Co., Ltd. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LY2189265 — Competitive Intelligence Brief. https://druglandscape.com/ci/ly2189265. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab